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Epidemiologic Links: Atopy
Asthma and rhinitis are frequently associated with
atopy with preferential sensitization to airborne
allergens. Atopic diseases can manifest them-
selves at different sites on the body and can pre-
sent as urticaria, allergic rhinitis, atopic dermati-
tis, conjunctivitis, food allergy, and asthma.
Allergic Rhinitis and Asthma Prevalence
Allergic rhinitis is an important health problem and
affects up to 40% of the worldwide population.1,2
Its prevalence in the Canadian population is
between 10 and 25%.1 Forty percent of allergic
rhinitis patients have asthma, and as much as 94%
of allergic asthma patients have allergic rhinitis.3–6
In Canada, the current prevalence of asthma is
8.4%7whereas worldwide prevalence varies from
1.6 to 37%.1
Allergic Rhinitis as a Risk Factor for Asthma
Settipane and colleagues conducted a prospec-
tive study on a cohort consisting of young 
university students to determine the long-term
risk factors for developing asthma and allergic
rhinitis.8 The follow-up study 23 years later
revealed that the incidence of asthma and allergic
rhinitis increases with age. Furthermore, the pres-
ence of allergic rhinitis and positive results of
allergen skin tests were shown to be important risk
factors of asthma development. Patients with aller-
gic rhinitis have a threefold greater chance of
developing asthma. Interestingly, the relief of
rhinitis symptoms over time correlates with the
improvement of asthma symptoms. Patients with
more severe and persistent rhinitis are at a higher
risk of developing asthma.9 A strong association
between perennial rhinitis and asthma in nonatopic
subjects was also demonstrated in the European
Community Respiratory Health Survey.10
To better understand the possible links between
asthma and allergic rhinitis, the World Health
Organization, through the Allergic Rhinitis and its
Impact on Asthma (ARIA) program, examined
the impact of allergic rhinitis on asthma.2 The
ARIA study concluded that allergic rhinitis is a
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major chronic respiratory disease owing to its
prevalence, impact on quality of life, impact on
school and work performance and productivity,
economic burden, and links to asthma. According
to the ARIA study and previous observations,
allergic and nonallergic rhinitis should be con-
sidered risk factors for asthma, along with other
known risk factors.
Physiopathologic Links
The mucous membranes of both the upper and the
lower airways are covered by a pseudostratified
columnar ciliated epithelium with a continuous
basement membrane. For this reason, these airways
share a mucosal susceptibility to inhaled 
allergens. The obvious anatomic difference is the
presence of smooth muscle in the lower airway 
as opposed to large venous sinusoids and 
prominent glands within the submucosa in the
upper airway. The following section describes
similarities and dissimilarities between rhinitis
and asthma pathologies.
Allergy
Exposure to an allergen triggers an immediate
reaction coordinated by mast cells and their medi-
ators such as histamines, leukotrienes, and
prostaglandins. In allergic rhinitis, this immediate
reaction leads to nasal congestion and runny nose
from an increase in vascular permeability. In
asthma, the immediate reaction results in bron-
chospasm. Late-phase reaction occurs in both
asthma and rhinitis following allergen exposure and
is mainly triggered by CD4+ T cells.11 Allergic
rhinitis and asthma share many pathologic features.
In fact, the same profile of inflammation, media-
tors, and adhesion molecules can be observed in
upper- and lower-airway allergic diseases. There
is a common cellular inflammation pattern char-
acterized by eosinophil, mast-cell, and CD4+T-cell
infiltration.12,13 Mediators (including histamine;
cysteinyl leukotrienes; interleukin [IL]-4, IL-5,
IL-13; regulated on activation, normal T-cell
expressed and secreted [RANTES] chemokine; and
eotaxin) are expressed in both upper and lower air-
ways.14,15 Although the initial inflammation
induced by allergens is similar in upper and lower
airways, the long-term structural consequences
differ. The respiratory epithelium is disrupted in
bronchial asthma whereas only minimal epithelial
shedding is observed in allergic rhinitis. The sub-
epithelial basement membrane is thickened with
an increased amount of collagen deposition in
asthma. Although this thickening can also occur
in the upper airway in rhinitis, the extent of this
process is less than that seen in the lower airway
in asthma.16
Allergic Rhinitis, Airway Hyperresponsiveness,
and Asthma
It is well established that 40% of nonasthmatic
patients with allergic rhinitis have increased air-
way hyperresponsiveness.17 Allergen nasal chal-
lenge or seasonal allergen exposure leads to
increased airway hyperresponsiveness in rhinitis
patients.18,19 The number of eosinophils in the
sputum correlates with nonspecific airway hyper-
responsiveness not only in asthma but also in
allergic seasonal rhinitis.20 Nasal eosinophilia cor-
relates with bronchial reactivity in allergic children
who have both asthma and rhinitis.21 Gaga and col-
leagues found eosinophilic infiltration in the nasal
mucosa of asthmatic patients even in the absence
of rhinitis.22The relationship between nasal allergy
and asymptomatic airway hyperresponsiveness
supports the concept of one airway, one disease.
Nonallergic Rhinitis and Nonallergic Asthma
An inflammatory pattern has been characterized
in asthmatic children suffering from allergic rhini-
tis and in those with nonallergic rhinitis.23 Sur-
prisingly, both groups have a typical T-helper 2
(Th2) cytokine inflammatory pattern as measured
in rhino-sinusal lavage. Nonatopic or intrinsic
asthmatic patients have an inflammatory pattern
similar to that of atopic asthma patients although
this nonatopic group has been less extensively
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granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF), and eosinophils were found in
endobronchial biopsy specimens from nonatopic
asthma patients.24-27 Even in the absence of an
allergic process, rhinitis and asthma share simi-
lar inflammatory profiles, linking both diseases.
Epidemiologic studies are consistent with these
findings, as nonatopic rhinitis has also been
reported to be an independent risk factor for
developing asthma.2
Allergic Challenge
To better understand the allergen relationship
between upper and lower airways, many studies
have examined this paradigm, using nasal or
bronchial allergen challenge and observing its
effect on the opposite site of the airway.
Effect of Nasal Allergen Exposure 
on Lower Airways
Nasal allergen challenge increases eosinophils
and adhesion molecules in both nasal and bronchial
biopsy specimens from nonasthmatic patients with
rhinitis.28 Chakir and colleagues also showed that
natural pollen exposure is associated with an
increase in lymphocyte numbers, eosinophil
recruitment, and IL-5 expression in the bronchial
mucosa of nonasthmatic persons with allergic
rhinitis.29 In another study, Chakir and colleagues
showed that allergic nonasthmatic patients with
seasonal pollen-induced rhinitis had airway patho-
logic changes (as seen in bronchial biopsy spec-
imens) similar to those observed in asthmatic
patients.30 These changes consisted of cellular
infiltration, mucosal edema, increased epithelial
desquamation, and focal basement-membrane
thickening.
Effect of Lower-Airway Allergen Exposure 
on Nasal Mucosa
Segmental bronchial allergen challenge in nonasth-
matic allergic rhinitis patients leads to a decrease
in nasal peak inspiratory flow and a concomitant
increase in nasal symptomatology.31 It also
increases eosinophils, eotaxin-positive cells, and
IL-5 expression in nasal mucosa biopsy speci-
mens31 and decreases mast cells.32The decrease in
the number of mast cells is attributed to a higher
rate of degranulation.
Mechanisms That Might Explain the Link
between Upper and Lower Airways
Anumber of mechanisms have been suggested to
explain the link between upper and lower air-
ways and the concept of united airway disease.
They include genetic factors, an anatomic link
between upper and lower airways, neural inter-
action between the nose and the lower airway, and
mediator- or inflammatory-cell circulation. Inflam-
matory mediators can reach the lower airway
from the upper airway through the airway pas-
sages. They might also be able to reach the lower
airway through the blood. A number of these
mediators, such as histamine, cysteinyl
leukotrienes, and some cytokines, have the abil-
ity to spill over into the systemic circulation.
However, very few data support this concept,
and most of the cytokines have a very short half-
life and do not act in an endocrine fashion. Inman33
and Denburg34 suggested that inflammatory medi-
ators such as IL-5 and GM-CSF can travel from
the lung to the bone marrow, where they could
stimulate the progenitors' release to the circula-
tion and to the target organs. We have shown that
after antigen challenge, there is an increase in IL-
5-producing T cells in the bone marrow and an
increase in high-affinity IL-5 receptor, which is
associated with an elevated number of eosinophil
progenitors.35,36 Recently, we showed that this
process is most likely due to retrograde migration
of antigen-specific Tcells from the airways to the
bone marrow, where antigen-specific Tcells can
produce a number of cytokines and help to release
and differentiate the progenitor cells.37 Progeni-
tor cells can be found along the entire airway in
atopic individuals38 and can differentiate into
mature eosinophils in response to local antigen
challenge39 (Figure 1).Treatment of Asthma and Allergic Rhinitis
As mentioned earlier, the pathophysiology of aller-
gic rhinitis is very similar to that of allergic asthma,
and the responses of the two conditions to phar-
macologic and immunologic interventions are
comparable. The most commonly used drugs for
both conditions are corticosteroids. However,
other anti-inflammatory drugs with systemic effects
have been recently introduced for the manage-
ment of both diseases.
Effect of Rhinitis Treatment on Asthma
Arecent meta-analysis of asthma outcomes and the
treatment of rhinitis with intranasal corticosteroids
failed to show any significant improvement in
asthma symptoms or in lung function40 although
a trend in favor of intranasal corticosteroids was
reported. In nonasthmatic children with allergic
rhinitis, intranasal corticosteroids significantly
improved airway hyperresponsiveness to metha-
choline but had no effect on asthma symptoms.41
Corren and colleagues reported that intranasal
corticosteroids prevent the increase of bronchial
responsiveness associated with seasonal pollen
exposure in allergic rhinitis patients with asthma.18
Other anti-inflammatory drugs (montelukast and
cetirizine), when used for rhinitis patients, have
also been reported to improve asthma symptoms
and to decrease the use of 2 agonists.42 Recent
studies have reported a decrease in asthma exac-
erbation in patients with concomitant allergic
rhinitis when these patients received any kind of
rhinitis treatment.43,44 Cetirizine, an antihistamine,
has shown effectiveness in relieving upper- and
lower-airway symptoms in patients suffering from
concomitant allergic rhinitis and asthma.45 Ceti-
rizine was found to be protective against late
bronchial hyperresponsiveness that follows nasal
allergen challenge in patients with allergic rhini-
tis.46 Combined therapy with montelukast and cet-
irizine for asthmatic patients with seasonal aller-
gic rhinitis lessens the need for a rescue inhaler and
improves lung function and asthma symptom
score to the same extent as does inhaled budesonide
combined with intranasal budesonide.47
Effect of Asthma Treatment on Rhinitis
Greiff and colleagues treated nonasthmatic aller-
gic rhinitis patients with inhaled corticosteroids
during pollen season. They found an inhibition of
the increase of eosinophils in blood and nasal tis-
sues that is usually observed in pollen season.48 The
patients who received inhaled budesonide had
significantly milder nasal symptoms. In a recent
clinical study, asthmatic individuals with nasal
84 Allergy, Asthma, and Clinical Immunology / Volume 1, Number 2, Spring 2005
Figure 1  Mechanisms that
might explain the link between
upper and lower airways. 
CNS = central nervous system.polyposis treated with montelukast had a 70%
improvement of nasal symptoms and a 60% to 90%
improvement in asthma clinical score.49 In a study
comparing treatment with montelukast alone to
treatment with inhaled and intranasal cortico-
steroids in patients with allergic rhinitis and in
patients with asthma, only the group treated with
corticosteroids showed a significant reduction in
nasal nitric oxide and in nasal peak flow, whereas
both treatments were efficient in decreasing rhini-
tis symptoms.50
Immunotherapy
Immunotherapy is reserved for patients with mod-
erately severe allergic rhinitis. Immunotherapy
reduces inflammatory-cell recruitment and acti-
vation as well as the secretion of mediators.2 In a
group of allergic rhinitis patients with asthma,
immunotherapy improved methacholine hyper-
reactivity and quality of life and reduced seasonal
asthma symptoms.51 Reducing the allergen sensi-
tivity not only leads to relief of rhinitis but also
helps control asthma (although less effectively).
Conclusion
It is important to carefully assess the upper air-
ways in asthmatic patients and the lower airways
in patients with allergic rhinitis. Allergic rhinitis
is an important risk factor for developing asthma
and is also an important cause of nonoptimal
control of asthma. Links between upper- and
lower-airway diseases exist through inflammatory
mediators, but other mechanisms, such as mouth
breathing and postnasal drip, can contribute.
Many therapeutic options are currently available
although corticosteroids remain the most effec-
tive anti-inflammatory drugs. Antileukotrienes
have beneficial effects on rhinitis and asthma
because they work through a systemic effect. Our
common approach to the treatment of asthma and
rhinitis needs to be revised to prevent the expres-
sion of the asthma phenotype in individuals who
have rhinitis and to achieve better control of
asthma in patients who already have both rhini-
tis and asthma.
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